CIP
TEVA icon

Champlain Investment Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Champlain Investment Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-7,000
Closed -$254K – 118
2016
Q4 		$254K Buy
7,000
+500
+8% +$20K ﹤0.01% 119
2016
Q3 		$299K Buy
+6,500
New +$339K ﹤0.01% 130

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Champlain Investment Partners's TEVA Position: Q1 2017 in Review

Champlain Investment Partners sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 7,000 shares — an estimated $254K sold.

Champlain Investment Partners first reported a position in TEVA in Q3 2016 and held it in 2 quarters. The position peaked at $299K in Q3 2016. 686 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

  • Champlain Investment Partners reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Champlain Investment Partners sold 7,000 Teva Pharmaceuticals shares in Q1 2017, an estimated $254K.
  • Champlain Investment Partners first reported a position in Teva Pharmaceuticals in Q3 2016 and held it in 2 quarters.
  • Champlain Investment Partners's Teva Pharmaceuticals position peaked at $299K in Q3 2016.
  • 686 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Champlain Investment Partners's 13F filing for Q1 2017, filed 12 May 2017.